Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI 571 in Advanced Soft Tissue Sarcoma
NCT00006357Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2000
- Primary completion
- Apr 2001
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of imatinib in soft tissue sarcoma (STS) and gastrointestinal stromal tumor (GIST) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Maximum Tolerated Dose up to 24 months, Pharmacokinetics up to 24 months and 2 more. Started Aug 2000; status: completed.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00006357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006357.